泊马度胺Pomalyst（pomalidomide）

INDICATIONS AND USAGE
Pomalidomide POMALYST is a thalidomide analog indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days after the end of the last therapy.

DOSAGE AND ADMINISTRATION
4 mg orally once daily for 1-21 days in a cycle repeated until disease progression. Refer to DEXAMETHASONE for dosage.

CONTRAINDICATIONS
Pregnancy

WARNINGS AND PRECAUTIONS
Hematologic Toxicity: Neutropenia is the most common Grade 3/4 adverse event. Monitor patients for hematologic toxicity, particularly neutropenia.
Hepatic: Hepatic failure including death; monitor liver function tests monthly.
Allergic Reactions: Angioedema and severe dermatologic reactions have been reported. Discontinue POMALYST for angioedema and severe dermatologic reactions.
Tumor Lysis Syndrome (TLS): Monitor patients at risk for TLS (i.e., those with high tumor burden) and take appropriate precautions.

Adverse reactions
The most common adverse reactions (≥30%) include fatigue and weakness, leukopenia, anemia, constipation, nausea, diarrhea, dyspnea, upper respiratory tract infection, back pain and fever.

Drug interactions
Strong CYP1A2 inhibitors: Avoid using strong CYP1A2 inhibitors unless medically necessary.

Use in special populations
Breastfeeding mothers: Please stop the drug or breastfeeding, taking into account the importance of the drug and considering the mother.
Avoid using POMALYST in patients with serum creatinine > 3.0 mg/dL.

Note: If the drug has a new packaging, the new packaging shall prevail. The above information comes from the Internet or is translated by student volunteers from higher medical colleges (if there are any errors or omissions, please help correct them). It is only for internal discussion among medical staff and is not used as any basis for medication. For specific medication instructions, please consult the attending physician.